Regenxbio Inc. (RGNX) Insider Trading

Last 12 months

Insiders bought $950k and sold $940k on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+$10k

1 buy · 4 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 1

executives and directors

Last open-market buy

Aug 2026

Aug 27, 2026

Get an email when RGNX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 26 – 27	Gregory Austin Ciongoli Director	Bought 2 parts	102,603	$9.25 average	$950k	665%	Form 4
Jul 2	Steve Pakola Chief Medical Officer	Sold10b5-1 plan	2,161	$13.64	$29k	1.0%	Form 4
Jun 29 – Jul 1	Steve Pakola Chief Medical Officer	Sold10b5-1 plan 2 parts	56,333	$12.23 average	$689k	21%	Form 4
May 11	Steve Pakola Chief Medical Officer	Sold10b5-1 plan	15,309	$11.02	$169k	6.2%	Form 4
Mar 10	Steve Pakola Chief Medical Officer	Sold10b5-1 plan	5,124	$10.35	$53k	2.0%	Form 4
Oct 9, 2025	Curran Simpson Chief Executive Officer	Sold10b5-1 plan	20,811	$12.62	$263k	8.8%	Form 4
Sep 29, 2025	Curran Simpson Chief Executive Officer	Sold10b5-1 plan	7,624	$10.03	$76k	3.1%	Form 4
Sep 10, 2025	Curran Simpson Chief Executive Officer	Sold10b5-1 plan	7,734	$10.02	$77k	3.1%	Form 4
May 12, 2025	Kenneth T. Mills Director	Sold10b5-1 plan	20,602	$7.91	$163k	4.2%	Form 4

Aug 26 – 27
Gregory Austin Ciongoli
Director · bought 102,603 at avg $9.25
$950k
665% of stake
Jul 210b5-1 plan
Steve Pakola
Chief Medical Officer · sold 2,161 at $13.64
$29k
1.0% of stake
Jun 29 – Jul 110b5-1 plan
Steve Pakola
Chief Medical Officer · sold 56,333 at avg $12.23
$689k
21% of stake
May 1110b5-1 plan
Steve Pakola
Chief Medical Officer · sold 15,309 at $11.02
$169k
6.2% of stake
Mar 1010b5-1 plan
Steve Pakola
Chief Medical Officer · sold 5,124 at $10.35
$53k
2.0% of stake
Oct 9, 202510b5-1 plan
Curran Simpson
Chief Executive Officer · sold 20,811 at $12.62
$263k
8.8% of stake
Sep 29, 202510b5-1 plan
Curran Simpson
Chief Executive Officer · sold 7,624 at $10.03
$76k
3.1% of stake
Sep 10, 202510b5-1 plan
Curran Simpson
Chief Executive Officer · sold 7,734 at $10.02
$77k
3.1% of stake
May 12, 202510b5-1 plan
Kenneth T. Mills
Director · sold 20,602 at $7.91
$163k
4.2% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RGNX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

IBRXImmunityBio, Inc.

BEAMBeam Therapeutics Inc.

AGENAgenus Inc.

DNAGinkgo Bioworks Holdings Inc.

AUTLAutolus Therapeutics plc

IPSCCentury Therapeutics, Inc.

VXRTVaxart Inc.

KYMRKymera Therapeutics Inc.

Spot a number that looks wrong? Check it in RGNX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RGNX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.